Clinical Trial

Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

Study acronym: OSCC
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Sintilimab) with targeted therapy (Cetuximab) as a possible treatment before and after surgery for locally advanced oral/pharyngeal squamous cell carcinoma.
Trial Details
NCT Number NCT07079410
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Enrollment 50 participants
Start Date 2025-07
Primary Completion 2027-07 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-23